ArticleRadiation protection dosimetry2025
Relative biological effectiveness of 31 meV thermal neutrons in peripheral blood lymphocytes.
Article in Radiation protection dosimetry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The reported relative biological effectiveness (RBE) for thermal neutrons has a large range (5-51, for cytogenetic endpoints), which can confound radiation protection decision-making. To determine whether thermal neutron spectra can influence RBE, the RBE of reactor-derived thermal neutrons of average energy 31 meV was evaluated in human peripheral blood lymphocytes using two classical DNA double-strand break endpoints: the dicentric chromosome assay (DCA) and the cytokinesis-block micronucleus assay. Dose-response curves for 41 to 408 mGy revealed a preference for linear regression. Maximum RBE (RBEM) values of 6.7 ± 0.9 and 4.4 ± 0.7 were calculated for the DCA and the micronucleus assay, respectively. These 31 meV RBEM values were significantly lower than our prior results for 64 meV thermal neutrons, which yielded a DCA RBEM of 11.3 ± 1.6 and a micronucleus RBEM of 9.0 ± 1.1. Dose-specific RBE values decreased with increasing dose for both assays. Microdosimetry simulations demonstrated similar quality factor values for both thermal neutron spectra. Dose deposition differences on the cellular scale, the difference in dose rate between irradiation configurations, or a not-yet understood phenomenon may be responsible for the RBE difference between the 31 and 64 meV thermal spectra. These findings indicate that the currently accepted radiation weighting factor wR value of 2.5 for thermal neutrons may underestimate the radiation detriment to small or shallow tissue targets including the lens of the eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.